431 related articles for article (PubMed ID: 33155698)
21. The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma.
Fulda S
Curr Cancer Drug Targets; 2009 Sep; 9(6):729-37. PubMed ID: 19754357
[TBL] [Abstract][Full Text] [Related]
22. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
23. Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs.
Ciaccio R; De Rosa P; Aloisi S; Viggiano M; Cimadom L; Zadran SK; Perini G; Milazzo G
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884690
[TBL] [Abstract][Full Text] [Related]
24. Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma.
Goldsmith KC; Hogarty MD
Cancer Lett; 2005 Oct; 228(1-2):133-41. PubMed ID: 15927359
[TBL] [Abstract][Full Text] [Related]
25. Mutations in PIK3CA are infrequent in neuroblastoma.
Dam V; Morgan BT; Mazanek P; Hogarty MD
BMC Cancer; 2006 Jul; 6():177. PubMed ID: 16822308
[TBL] [Abstract][Full Text] [Related]
26. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
Berry T; Luther W; Bhatnagar N; Jamin Y; Poon E; Sanda T; Pei D; Sharma B; Vetharoy WR; Hallsworth A; Ahmad Z; Barker K; Moreau L; Webber H; Wang W; Liu Q; Perez-Atayde A; Rodig S; Cheung NK; Raynaud F; Hallberg B; Robinson SP; Gray NS; Pearson AD; Eccles SA; Chesler L; George RE
Cancer Cell; 2012 Jul; 22(1):117-30. PubMed ID: 22789543
[TBL] [Abstract][Full Text] [Related]
27. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
Shukla N; Ameur N; Yilmaz I; Nafa K; Lau CY; Marchetti A; Borsu L; Barr FG; Ladanyi M
Clin Cancer Res; 2012 Feb; 18(3):748-57. PubMed ID: 22142829
[TBL] [Abstract][Full Text] [Related]
28. Methodological advances in the discovery of novel neuroblastoma therapeutics.
Segura MF; Soriano A; Roma J; Piskareva O; Jiménez C; Boloix A; Fletcher JI; Haber M; Gray JC; Cerdá-Alberich L; Martínez de Las Heras B; Cañete A; Gallego S; Moreno L
Expert Opin Drug Discov; 2022 Feb; 17(2):167-179. PubMed ID: 34807782
[TBL] [Abstract][Full Text] [Related]
29. A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma.
Mlakar V; Morel E; Mlakar SJ; Ansari M; Gumy-Pause F
J Exp Clin Cancer Res; 2021 Jun; 40(1):189. PubMed ID: 34103089
[TBL] [Abstract][Full Text] [Related]
30. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
[TBL] [Abstract][Full Text] [Related]
31. Neuroblastoma: Emerging trends in pathogenesis, diagnosis, and therapeutic targets.
Katta SS; Nagati V; Paturi ASV; Murakonda SP; Murakonda AB; Pandey MK; Gupta SC; Pasupulati AK; Challagundla KB
J Control Release; 2023 May; 357():444-459. PubMed ID: 37023798
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic Targeting of Non-oncogene Dependencies in High-risk Neuroblastoma.
Huang CT; Hsieh CH; Lee WC; Liu YL; Yang TS; Hsu WM; Oyang YJ; Huang HC; Juan HF
Clin Cancer Res; 2019 Jul; 25(13):4063-4078. PubMed ID: 30952635
[TBL] [Abstract][Full Text] [Related]
33. Advances in pharmacotherapy for neuroblastoma.
Pezeshki PS; Moeinafshar A; Ghaemdoust F; Razi S; Keshavarz-Fathi M; Rezaei N
Expert Opin Pharmacother; 2021 Dec; 22(17):2383-2404. PubMed ID: 34254549
[TBL] [Abstract][Full Text] [Related]
34. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
[TBL] [Abstract][Full Text] [Related]
35. Targeting anaplastic lymphoma kinase in neuroblastoma.
Umapathy G; Mendoza-Garcia P; Hallberg B; Palmer RH
APMIS; 2019 May; 127(5):288-302. PubMed ID: 30803032
[TBL] [Abstract][Full Text] [Related]
36. YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.
Coggins GE; Farrel A; Rathi KS; Hayes CM; Scolaro L; Rokita JL; Maris JM
Cancer Res; 2019 Dec; 79(24):6204-6214. PubMed ID: 31672841
[TBL] [Abstract][Full Text] [Related]
37. Neuroblastoma: Essential genetic pathways and current therapeutic options.
Salemi F; Alam W; Hassani MS; Hashemi SZ; Jafari AA; Mirmoeeni SMS; Arbab M; Mortazavizadeh SMR; Khan H
Eur J Pharmacol; 2022 Jul; 926():175030. PubMed ID: 35605657
[TBL] [Abstract][Full Text] [Related]
38. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.
Janku F; Kaseb AO; Tsimberidou AM; Wolff RA; Kurzrock R
Oncotarget; 2014 May; 5(10):3012-22. PubMed ID: 24931142
[TBL] [Abstract][Full Text] [Related]
39. Genetic discoveries and treatment advances in neuroblastoma.
Bagatell R; Cohn SL
Curr Opin Pediatr; 2016 Feb; 28(1):19-25. PubMed ID: 26576010
[TBL] [Abstract][Full Text] [Related]
40. Neuroblastoma models for insights into tumorigenesis and new therapies.
Kiyonari S; Kadomatsu K
Expert Opin Drug Discov; 2015 Jan; 10(1):53-62. PubMed ID: 25345447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
